As part of Octapharma’s long-standing commitment to addressing the unmet clinical needs of people with von Willebrand disease, Octapharma continues to carry out clinical trials to better illuminate the clinical efficacy and safety of wilate® in different patient populations.
Link to the trial on clinicaltrials.gov: VIP study
The von Willebrand factor in pregnancy (VIP) study is a prospective, multicenter, investigator-initiated study aiming to increase our understanding of postpartum bleeding in women with von Willebrand disease.
For more details, visit:
vipstudy.com or clinicaltrials.gov
Principal Investigators
Jill M. Johnsen MD
University of Washington, Seattle, WA, USA
Barbara A. Konkle MD
University of Washington, Seattle, WA, USA
A multicenter pilot crossover trial of prophylactic wilate® compared to placebo for heavy menstrual bleeding in patients with low von Willebrand factor and von Willebrand disease (EMPOWER)
Principal Investigator
Michelle Sholzberg MDCM
Srivastava A et al. Haemophilia 2017; 23:264–72.
Windyga J and von Depka-Prondzinski M. Thromb Haemost 2011; 105:1072–9.
Berntorp E and Windyga J. Haemophilia 2009; 15:122–30.
Stadler M et al. Biologicals 2006; 34:281–8.
Kessler CM et al. Thromb Haemost 2011; 106:279–88.
wilate® Full Prescribing Information. Paramus, NJ: Octapharma; rev July 2026.
Sholzberg M et al. TH Open 2021; 5:e264–72.
Octapharma AG, data on file.
Link: Octapharma Quality and Safety, last accessed July 2021.
Please see wilate® full Prescribing Information.
Indication
wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in adult and pediatric patients with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes. wilate® is also indicated in adult and pediatric patients 12 years of age and older with hemophilia A for on-demand treatment and control of bleeding episodes; and for routine prophylaxis to reduce the frequency of bleeding episodes.
Contraindications
Do not use in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reaction, to human plasma-derived products, any ingredient in the formulation, or components of the container.
Warnings and Precautions
Adverse Reactions
The most common adverse reactions (≥ 1%) in clinical trials on VWD were hypersensitivity reactions, urticaria, chest discomfort, and dizziness. The most common adverse reaction (≥ 1%) in clinical trials in hemophilia A was pyrexia (fever).
Please see wilate® full Prescribing Information.
Please see wilate® full Prescribing Information.
Indication
wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in adult and pediatric patients with von Willebrand disease for on-demand treatment and control of bleeding episodes; for perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes. wilate® is also indicated in adult and pediatric patients 12 years of age and older with hemophilia A for on-demand treatment and control of bleeding episodes; and for routine prophylaxis to reduce the frequency of bleeding episodes.
Contraindications
Do not use in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reaction, to human plasma-derived products, any ingredient in the formulation, or components of the container.
Warnings and Precautions
Adverse Reactions
The most common adverse reactions (≥ 1%) in clinical trials on VWD were hypersensitivity reactions, urticaria, chest discomfort, and dizziness. The most common adverse reaction (≥ 1%) in clinical trials in hemophilia A was pyrexia (fever).
Please see wilate® full Prescribing Information.
Octapharma does not review, endorse, or control the content of any non-Octapharma site. Octapharma is not responsible for the accuracy, content, practices, or standards of any non-Octapharma resources accessed through a link on this site. Octapharma provides general information for educational purposes. This site does not provide medical advice, diagnosis, or treatment to you. Always consult your physician to help decide a treatment plan or other medical advice.
The information on this website has been specifically created for U.S. healthcare professionals (HCPs)
Please see wilate® full Prescribing Information